TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Herceptin
Drug Type Antibody
TTD ID D04WFL
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 134
Ref_1
Pair Name Flavokawain A, Herceptin
Partner Name Flavokawain A
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression BCL2L11 KEGG ID N.A.
Down-regulation Expression BCL-xL hsa598
Up-regulation Expression BIM hsa10018
Down-regulation Phosphorylation CDC25C hsa995
Down-regulation Phosphorylation CDK1 hsa983
Down-regulation Expression ERBB2 hsa2064
Down-regulation Expression ERBB2 hsa2064
Down-regulation Expression MYT1 hsa4661
Down-regulation Expression SKP2 hsa6502
Down-regulation Expression WEE1 hsa7465
Down-regulation Expression XIAP hsa331
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
MDA-MB-468 Breast adenocarcinoma Homo sapiens (Human) CVCL_0419
Result Our results suggest FKA as a promising and novel apoptosis inducer and G2 blocking agent that, in combination with Herceptin, enhances for the treatment of HER2-overexpressing breast cancer.
03. Reference
No. Title Href
1 Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin. Molecules. 2017 Mar 14;22(3):462. doi: 10.3390/molecules22030462. Click
It has been 26556 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP